- Home
- AMBP vs DYN Comparison
AMBP vs DYN Comparison
Compare AMBP & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBP
- DYN
- Stock Information
- Founded
- AMBP 2021
- DYN 1984
- Country
- AMBP Luxembourg
- DYN United States
- Employees
- AMBP N/A
- DYN N/A
- Industry
- AMBP Containers/Packaging
- DYN Medicinal Chemicals and Botanical Products
- Sector
- AMBP Industrials
- DYN Health Care
- Exchange
- AMBP Nasdaq
- DYN Nasdaq
- Market Cap
- AMBP 2.4B
- DYN 1.9B
- IPO Year
- AMBP N/A
- DYN 2020
- Fundamental
- Price
- AMBP $3.74
- DYN $16.48
- Analyst Decision
- AMBP Hold
- DYN Strong Buy
- Analyst Count
- AMBP 6
- DYN 14
- Target Price
- AMBP $4.17
- DYN $34.93
- AVG Volume (30 Days)
- AMBP 1.2M
- DYN 2.7M
- Earning Date
- AMBP 10-23-2025
- DYN 11-11-2025
- Dividend Yield
- AMBP 10.47%
- DYN N/A
- EPS Growth
- AMBP N/A
- DYN N/A
- EPS
- AMBP N/A
- DYN N/A
- Revenue
- AMBP $5,231,000,000.00
- DYN N/A
- Revenue This Year
- AMBP $11.74
- DYN N/A
- Revenue Next Year
- AMBP $2.02
- DYN N/A
- P/E Ratio
- AMBP N/A
- DYN N/A
- Revenue Growth
- AMBP 8.39
- DYN N/A
- 52 Week Low
- AMBP $2.50
- DYN $6.36
- 52 Week High
- AMBP $4.78
- DYN $35.90
- Technical
- Relative Strength Index (RSI)
- AMBP 48.13
- DYN 70.62
- Support Level
- AMBP $3.65
- DYN $13.73
- Resistance Level
- AMBP $3.83
- DYN $17.00
- Average True Range (ATR)
- AMBP 0.10
- DYN 0.77
- MACD
- AMBP -0.01
- DYN 0.33
- Stochastic Oscillator
- AMBP 31.65
- DYN 88.82
About AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.